Sermorelin Therapy

Growth hormone is not released steadily. Your hypothalamus sends pulses of growth hormone releasing hormone (GHRH) to the pituitary, which responds with bursts of growth hormone — the largest of them during early slow-wave sleep. A second hypothalamic hormone, somatostatin, applies the brakes. The whole system is a push-and-pull, and it winds down with age: growth hormone output declines roughly 15% per decade after your twenties, largely because the GHRH signal weakens rather than because the pituitary stops working.

Sermorelin is a 29-amino-acid peptide matching the active fragment of GHRH. Injected before bed, it restores that signal at the point in the circadian cycle when your pituitary is most primed to respond. Growth hormone released this way then acts partly directly and partly by prompting the liver to produce IGF-1, which mediates most of the downstream effects on tissue.

The important structural point is that your pituitary is still in charge. Somatostatin and circulating IGF-1 continue to apply negative feedback, which caps output at physiological levels. That is the safety advantage over injecting growth hormone directly — and it is also why the effect is smaller. You cannot use sermorelin to push growth hormone above what your own pituitary is willing to release.

Active malignancy is an absolute exclusion. Growth hormone and IGF-1 are growth-promoting signals. Whether raising them meaningfully affects existing tumor tissue is not settled, and it is not a question worth answering on a patient. Sermorelin is also avoided in pregnancy and breastfeeding, in active proliferative diabetic retinopathy, during acute critical illness, and where there is a known pituitary tumor or a history of pituitary surgery or cranial irradiation unless an endocrinologist has cleared it. Uncontrolled diabetes and untreated hypothyroidism are treated first, because both distort the growth hormone axis and would make any result uninterpretable.

It will not do what HGH marketing claims. It does not reverse aging, remove wrinkles, regrow hair, or add substantial muscle. Where studies show benefit on body composition, the changes are measured in single-digit pounds over months, and they appear alongside training and adequate protein rather than instead of them.

It will not work if your pituitary cannot respond. Sermorelin depends on a functioning pituitary. If the gland itself is the problem — following surgery, radiation, or structural disease — signaling it harder achieves nothing, and that is an endocrinology referral rather than a peptide protocol.

It will not fix a sleep problem with another cause. Untreated obstructive sleep apnea is common and is itself a cause of low growth hormone output, daytime fatigue, and weight gain. If your history suggests apnea, we will say so and point you toward a sleep study rather than treating around it.

The long-term data is limited. Most published work on GHRH analogs covers months rather than years, and much of it is in adults with documented growth hormone deficiency rather than healthy adults with age-related decline. That does not make it unsafe. It does mean anyone promising you certainty is overstating what is known.